Literature DB >> 16596784

Cannabinoid function in learning, memory and plasticity.

G Riedel1, S N Davies.   

Abstract

Marijuana and its psychoactive constituents induce a multitude of effects on brain function. These include deficits in memory formation, but care needs to be exercised since many human studies are flawed by multiple drug abuse, small sample sizes, sample selection and sensitivity of psychological tests for subtle differences. The most robust finding with respect to memory is a deficit in working and short-term memory. This requires intact hippocampus and prefrontal cortex, two brain regions richly expressing CB1 receptors. Animal studies, which enable a more controlled drug regime and more constant behavioural testing, have confirmed human results and suggest, with respect to hippocampus, that exogenous cannabinoid treatment selectively affects encoding processes. This may be different in other brain areas, for instance the amygdala, where a predominant involvement in memory consolidation and forgetting has been firmly established. While cannabinoid receptor agonists impair memory formation, antagonists reverse these deficits or act as memory enhancers. These results are in good agreement with data obtained from electrophysiological recordings, which reveal reduction in neural plasticity following cannabinoid treatment, and increased plasticity following antagonist exposure. The mixed receptor properties of the pharmacological tool, however, make it difficult to define the exact role of any CB1 receptor population in memory processes with any certainty. This makes it all the more important that behavioural studies use selective administration of drugs to specific brain areas, rather than global administration to whole animals. The emerging role of the endogenous cannabinoid system in the hippocampus may be to facilitate the induction of long-term potentiation/the encoding of information. Administration of exogenous selective CB1 agonists may therefore disrupt hippocampus-dependent learning and memory by 'increasing the noise', rather than 'decreasing the signal' at potentiated inputs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596784     DOI: 10.1007/3-540-26573-2_15

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  51 in total

1.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

2.  Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

Authors:  Anushka V Goonawardena; Lianne Robinson; Robert E Hampson; Gernot Riedel
Journal:  Learn Mem       Date:  2010-09-28       Impact factor: 2.460

Review 3.  The endocannabinoid system and extinction learning.

Authors:  Beat Lutz
Journal:  Mol Neurobiol       Date:  2007-08-17       Impact factor: 5.590

4.  The endocannabinoid system and Alzheimer's disease.

Authors:  Cristina Benito; Estefanía Núñez; María Ruth Pazos; Rosa María Tolón; Julián Romero
Journal:  Mol Neurobiol       Date:  2007-09-05       Impact factor: 5.590

5.  Electrical stimulation therapies for CNS disorders and pain are mediated by competition between different neuronal networks in the brain.

Authors:  Carl L Faingold
Journal:  Med Hypotheses       Date:  2008-08-30       Impact factor: 1.538

6.  Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

Authors:  Deepak Cyril D'Souza; Brian Pittman; Edward Perry; Arthur Simen
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

7.  Cannabinoids in exhaled breath following controlled administration of smoked cannabis.

Authors:  Sarah K Himes; Karl B Scheidweiler; Olof Beck; David A Gorelick; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-09-17       Impact factor: 8.327

Review 8.  Cannabis effects on driving skills.

Authors:  Rebecca L Hartman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-12-07       Impact factor: 8.327

Review 9.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 10.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.